About
Cannenta is a biotechnology venture developing advanced wound care products. The company has a unique angiogenic factor which can be incorporated in a range of dressing products to accelerate vascularisation in wound beds and thus provide a foundation for effective wound recovery. The technology can be applied to a range of products and indications including treatment of diabetic foot ulcers and other chronic wounds. Cannenta is working with established manufacturers to incorporate the technology into suitable product carriers and intends to distribute to a global market following a clinical development program.
Technologies
Outlook
Mobile Friendly
YouTube
WordPress.org
Remote
AI
Keywords
medical equipment manufacturing
vegf stimulation
chronic wounds
biotechnology
chronic wound treatment
medical devices
clinical trials
regulatory approval
services
pro-angiogenic products
wound care in emerging markets
laboratory and animal trials
product registration
market expansion
wound bed vascularization
diabetic wound therapy
biodegradable hydrogels
product commercialization
e-beam crosslinked hydrogels
clinical development
patient care
advanced biomaterials
strategic partnerships
angiogenesis factor
biotech
vegf upregulation
sugar-based technology
pharmaceuticals
hydrogel manufacturing
wound healing
Company Information
-
Employees 5
-
Founded 2018
Location
Melbourne, Victoria, Australia
